An engineered IgG induces degradation of endogenous IgG, providing a potential therapeutic approach to autoimmune disease.
References
Vaccaro, C. et al. Nat. Biotechnol. 23, 1283–1288 (2005).
Junghans, R.P. Immunol. Res. 16, 29–57 (1997).
Martin, W.L., West, A.P. Jr., Gan, L. & Bjorkman, P.J. Molec. Cell. 7, 867–877 (2001).
Bitonti, A.J. et al. Proc. Natl. Acad. Sci. USA 101, 9763–9768 (2004).
Hinton, P.R. et al. J. Biol. Chem. 279, 6213–6216 (2004).
Akilesh, S. et al. J. Clin. Invest. 113, 1328–1333 (2004).
Liu, Z. et al. J. Exp. Med. 186, 777–783 (1997).
Jin, F. & Balthasar, J.P. Hum. Immunol. 66, 403–410 (2005).
Dall' Acqua, W.F. et al. J. Immunol. 169, 5171–5180 (2002).
Ghetie, V. et al. Nat. Biotechnol. 15, 637–640 (1997).
Samuelsson, A., Towers, T.L. & Ravetch, J.V. Science 291, 484–486 (2001).
Getman, K.E. & Balthasar, J.P. J. Pharm. Sci. 94, 718–729 (2005).
Roopenian, D.C. et al. J. Immunol. 170, 3528–3533 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blumberg, R., Lencer, W. Antibodies in the breakdown lane. Nat Biotechnol 23, 1232–1234 (2005). https://doi.org/10.1038/nbt1005-1232
Issue Date:
DOI: https://doi.org/10.1038/nbt1005-1232
- Springer Nature America, Inc.